Skip to main content


CEEHRC / Postdoctoral fellow in cancer genomics /

As part of The Princess Margaret Cancer Centre, a top five cancer research centre in North America, Dr. Mathieu Lupien is currently seeking applications for a wet lab postdoctoral fellow in cancer genomics, with focused interests in chromatin and epigenetic research.

The Lupien laboratory is committed to bringing the best tailored therapy to cancer patients through its innovative discoveries and methodologies in chromatin and epigenetic-based research to find the genetic determinants of oncogenesis.

The applicant will be responsible to lead research projects to identify the genetic determinants of recurrence in hormone-dependent cancers (breast and/or prostate cancer) using the latest chromatin and epigenetic-based technologies (single-cell ATAC/RNAseq, Hi-C, ChIPseq, etc). They will also work towards identifying new treatment options for patients using drug target identification and repurposing strategies that will be functionally validated in patient-derived models, including organoids, xenograft and explants.

Applicants should expect to:

  • Lead independent research projects
  • Demonstrate willingness to conduct leading edge chromatin & epigenetics research
  • Apply fundamental knowledge of research principles, theories and concepts
  • Contribute to the development of new epigenetic assays relying on sequencing-based technologies.
  • Optimize and improve epigenomic assays by analyzing problems of moderate scope and complexity through a scientific approach
  • Demonstrate excellent competency in written and verbal communications
  • Readily engage with a diverse research team

By joining the Lupien laboratory you will benefit from four organization assets:

  • Complementary team composition: The research team consists of highly qualified trainees with expertise in computational sciences and in experimental oncology engaged in the design and implementation of state-of-the-art software as well as the adoption and development of the latest chromatin & epigenetic technologies.
  • Partnerships accelerating our clinical impact: We collaborate with national and international clinician-scientists to address the most pressing needs for cancer patients. We partner with scientists across diverse disciplines to conduct research at the leading edge of innovation and transform tomorrow’s care.
  • State-of-the-art infrastructure and comprehensive resources: The Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world, and Canada’s largest cancer research and treatment centre. Its infrastructure and resources enable research at the forefront of clinical transformation by accelerating the conversion of basic and translational discoveries into the clinical setting.
  • Hosted in the 6IX: Toronto is the fourth largest city in North America and one of the world's most multicultural cities. With a committed discovery district and a growing reputation as the global home of Artificial Intelligence, Toronto is home to the fastest growing tech ecosystem in North America and provides unique opportunities for the commercialization of discoveries. Toronto is the city on hyperdrive, the land of multitude that opens your curiosity and broadens your horizons.

Candidates should have a strong background in epigenetics, genomics, molecular biology and/or biochemistry, hold a doctoral degree in a relevant field, be looking for a collaborative and dynamic environment, and have a track record of productivity and innovation. Prior experience in generating and analyzing omics datasets is an asset but not a requirement. The salary of this yearly renewable position will be established according to institutional guidelines.

For more information on research interests and publications from the Lupien lab follow us on Twitter or visit the lab website.

Please forward current curriculum vitae including a publication list and names of three references to

We thank all applicants for applying, however, only those selected for an interview will be contacted.

The Princess Margaret Cancer Centre, Toronto
Date posted: